Although some studies found considerable clinical improvements resulting from treatment with IL-6 blockers (236–239), others do not report any significant difference between the clinical features of groups treated with anti-IL6/IL-6R mAbs and their respective controls (without anti-IL-6/IL-6R) (240–243).